In a mouse CML model, treatment comprising a combination of imatinib and a PAI‐1 inhibitor, TM5614, substantially improved therapeutic outcomes of the TKI, demonstrated by fewer CML cells in the BM and extended survival. The gene discussed is SERPINE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.